No Data
Press Release: Sisram Medical Announces 2024 Annual Results
SISRAM MED announces its full-year performance for 2024.
Leading the market with strategic resilience to promote regional breakthroughs and Global collaborative development. Hong Kong, March 19, 2025 /PR Newswire/ -- SISRAM MED Co., Ltd. (English "Sisram"; referred to as "the Company" or "SISRAM MED", stock code: 1696.HK, together with its subsidiaries referred to as "the Group"), today announced its audited consolidated annual results for the year ended December 31, 2024 ("the Reporting Period"). SISRAM MED is a Global beauty and health group, and its unique beauty and health ecosystem provides a diverse range of offerings centered on energy source devices and injection fillers.
SISRAM MED (01696.HK) annual revenue is 0.349 billion USD, a decrease of 2.8% year-on-year.
On March 19, Gelonghui reported that SISRAM MED (01696.HK) announced its earnings for the year ending December 31, 2024, amounting to 349.1 million USD, a decrease of 2.8% compared to last year's earnings. The gross margin increased from 61.1% in the same period of 2023 to 62.1% for the reporting period. The annual profit was 28.8 million USD, a decrease of 12.6% compared to last year. The Board of Directors has decided to declare a final dividend of 0.126 HKD per share (including tax). For the year ending December 31, 2024, direct sales revenue accounted for 87% of total revenue, compared to 78% in the same period of 2023. As of 202
SISRAM MED (01696) will distribute a final dividend of HKD 0.126 per share.
SISRAM MED (01696) announced that it will distribute the final dividend for the year ending December 31, 2024...
Express News | Sisram Medical FY Gross Margin 62.1%
Express News | Sisram Medical FY Net Income USD 28.8 Million
Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Stock Yet As It Plummets 27%
